KRAS and non-small cell lung carcinoma: D’Incecco et al. 6examined PD-1 and PD-L1 expression via immunohistochemistry in a cohort of 125 NSCLC patients, 30 of whom where “triple negative” (wild-type EGFR, ALK, and KRAS) and the other 95 were EGFR-mutant, KRAS-mutant, or ALK translocated.